Share This Page
ABACAVIR SULFATE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Abacavir Sulfate, and what generic alternatives are available?
Abacavir Sulfate is a drug marketed by Aurobindo Pharma Ltd, Hetero Labs Ltd Iii, Apotex Inc, Chartwell Rx, Cipla, Mylan Pharms Inc, Pharmobedient, Aurobindo Pharma, Hetero Labs Ltd V, Laurus, Macleods Pharms Ltd, Teva Pharms Usa, Zydus Pharms, and Lupin Ltd. and is included in nineteen NDAs.
The generic ingredient in ABACAVIR SULFATE is abacavir sulfate; lamivudine; zidovudine. There are twelve drug master file entries for this compound. Additional details are available on the abacavir sulfate; lamivudine; zidovudine profile page.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for ABACAVIR SULFATE?
- What are the global sales for ABACAVIR SULFATE?
- What is Average Wholesale Price for ABACAVIR SULFATE?
Summary for ABACAVIR SULFATE
| US Patents: | 0 |
| Applicants: | 14 |
| NDAs: | 19 |
| Finished Product Suppliers / Packagers: | 12 |
| Raw Ingredient (Bulk) Api Vendors: | 89 |
| Clinical Trials: | 65 |
| DailyMed Link: | ABACAVIR SULFATE at DailyMed |
Paragraph IV (Patent) Challenges for ABACAVIR SULFATE
| Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
|---|---|---|---|---|---|---|
| ZIAGEN | Oral Solution | abacavir sulfate | 20 mg/mL | 020978 | 1 | 2012-12-27 |
| ZIAGEN | Tablets | abacavir sulfate | 300 mg | 020977 | 1 | 2009-01-28 |
US Patents and Regulatory Information for ABACAVIR SULFATE
Abacavir Sulfate: Market Dynamics and Financial Trajectory
Abacavir sulfate is a nucleoside reverse transcriptase inhibitor (NRTI) used in combination therapy for the treatment of human immunodeficiency virus (HIV) infection. The market for abacavir sulfate is characterized by established therapeutic use, generic competition, and ongoing efforts to manage its associated hypersensitivity reaction.
What is the Current Market Size and Growth Rate for Abacavir Sulfate?
The global market for abacavir sulfate is substantial, driven by its inclusion in highly active antiretroviral therapy (HAART) regimens. Exact current market size figures can fluctuate based on reporting periods and inclusion of specific combination products. However, analyses estimate the market for HIV drugs, which abacavir sulfate contributes to, to be in the tens of billions of U.S. dollars annually. For example, the global HIV market was valued at approximately $28.8 billion in 2022 and is projected to reach $36.6 billion by 2030, growing at a compound annual growth rate (CAGR) of 3.1% from 2023 to 2030 (1). Abacavir sulfate's specific contribution is difficult to isolate due to its frequent use in fixed-dose combinations.
Growth in the abacavir sulfate market is influenced by several factors:
- Prevalence of HIV: The continued global prevalence of HIV, particularly in sub-Saharan Africa, Asia, and parts of the Americas, sustains demand for antiretroviral therapies.
- Treatment Guidelines: Inclusion in World Health Organization (WHO) and national treatment guidelines as a preferred or alternative first-line and second-line treatment option for HIV-1 infection.
- Generic Competition: The availability of generic abacavir sulfate formulations has increased accessibility and driven down prices, impacting overall market value but potentially increasing volume.
- Development of New Therapies: The emergence of newer antiretroviral agents and long-acting injectables may gradually impact the market share of older therapies like abacavir sulfate, although established regimens often maintain strong market presence due to efficacy, cost-effectiveness, and patient familiarity.
- Geographic Market Penetration: Expansion of access to antiretroviral therapy in low- and middle-income countries remains a key driver for sustained demand.
The market trajectory for abacavir sulfate is therefore one of mature product demand, influenced by public health initiatives, pricing pressures from generics, and the evolving landscape of HIV treatment innovation.
What are the Key Indications and Therapeutic Applications of Abacavir Sulfate?
Abacavir sulfate is indicated for the treatment of HIV-1 infection in combination with other antiretroviral agents. It is not used as monotherapy. Its primary therapeutic applications are within the framework of combination antiretroviral therapy (cART), formerly known as HAART.
The key indications and applications include:
- First-line Treatment: Abacavir is a component of several recommended first-line regimens for treatment-naive HIV-1 infected adults and children. Its use is often contingent on genetic testing for the HLA-B*5701 allele due to the risk of hypersensitivity reaction.
- Second-line Treatment: It can be used in patients who have developed resistance to other antiretroviral drugs or who have experienced intolerance to other agents.
- Components of Fixed-Dose Combinations (FDCs): Abacavir is most commonly administered as part of FDCs, which simplify treatment regimens and improve adherence. Notable FDCs containing abacavir include:
- Kivexa (abacavir sulfate/lamivudine)
- Triumeq (abacavir sulfate/dolutegravir/lamivudine)
- Trizivir (abacavir sulfate/lamivudine/zidovudine)
- Epzicom (abacavir sulfate/lamivudine) – U.S. brand name for Kivexa.
- Treatment of Pediatric Patients: Abacavir is approved for use in pediatric patients as part of combination therapy, with specific dosing recommendations based on age and weight.
The efficacy of abacavir sulfate is linked to its mechanism of action, which inhibits HIV-1 reverse transcriptase, an enzyme essential for viral replication. By blocking this enzyme, abacavir sulfate prevents the conversion of viral RNA into DNA, thereby halting the replication cycle of the virus.
What is the Patent Landscape and Exclusivity Status for Abacavir Sulfate?
The original patents protecting abacavir sulfate have long expired, leading to widespread generic availability. The pioneering development and patenting of abacavir sulfate were primarily associated with GlaxoSmithKline (GSK).
- Original Patents: U.S. Patent 5,414,007, filed in 1993 and granted in 1995, is a foundational patent for abacavir and its analogs. This patent, along with others covering synthesis, formulations, and therapeutic uses, would have expired within the typical 20-year patent term (plus potential extensions).
- Market Exclusivity: Given the patent expirations, abacavir sulfate is now a fully genericized drug. This means that multiple pharmaceutical companies can manufacture and market abacavir sulfate and its formulations.
- Combination Products: While the patents for abacavir itself have expired, patents on specific fixed-dose combinations (FDCs) or novel formulations incorporating abacavir may have had different expiration dates or have been subject to patent litigation. For example, patents covering Triumeq (abacavir sulfate/dolutegravir/lamivudine) have been the subject of litigation, impacting market exclusivity for specific brands of this FDC. However, the abacavir component within such FDCs benefits from generic availability once its primary patents expire.
- Regulatory Exclusivities: Data exclusivity periods granted by regulatory agencies (e.g., FDA in the U.S., EMA in Europe) upon approval of new drug applications also play a role. However, for a molecule as established as abacavir sulfate, these exclusivities are largely historical.
The absence of active patent protection for abacavir sulfate as a single entity means that market access and competitive dynamics are now driven by manufacturing capabilities, cost of goods, and the patent status of newer combination partners within FDCs.
Who are the Major Manufacturers and Competitors in the Abacavir Sulfate Market?
The market for abacavir sulfate is now characterized by numerous generic manufacturers competing with the original innovator, GSK, particularly in its branded formulations and FDCs.
Key Players and Competitors:
-
Innovator (Historically): GlaxoSmithKline (GSK) – The developer of abacavir, marketed under brands like Ziagen (abacavir sulfate) and in combination products. GSK remains a significant player with branded FDCs such as Triumeq.
-
Major Generic Manufacturers: A multitude of generic pharmaceutical companies produce and market abacavir sulfate API (Active Pharmaceutical Ingredient) and finished dosage forms. These include, but are not limited to:
- Teva Pharmaceutical Industries Ltd.
- Mylan N.V. (now Viatris)
- Sun Pharmaceutical Industries Ltd.
- Cipla Ltd.
- Hetero Drugs Limited
- Lupin Ltd.
- Dr. Reddy's Laboratories Ltd.
- Aurobindo Pharma Ltd.
- Apotex Inc.
- Gilead Sciences, Inc. (while primarily known for other HIV therapies, may have licensing or manufacturing involvement).
-
Fixed-Dose Combination (FDC) Manufacturers: Companies that market FDCs containing abacavir sulfate are key competitors. This includes both innovator companies (e.g., GSK with Triumeq, Kivexa/Epzicom) and generic manufacturers who have successfully developed and received approval for generic versions of these FDCs. For example, generic versions of abacavir/lamivudine and abacavir/dolutegravir/lamivudine are available from various generic players.
Competitive Dynamics:
The competitive landscape is driven by:
- Price: Generic competition exerts significant downward pressure on pricing.
- Availability: Generic manufacturers aim for broad market access through various distribution channels, including direct sales to pharmacies, wholesalers, and government procurement programs.
- Quality and Bioequivalence: Generic products must demonstrate bioequivalence to the branded product to gain regulatory approval.
- Manufacturing Capacity: The ability to produce abacavir sulfate API and finished products at scale is crucial.
- Market Share in FDCs: Competition for market share within highly successful FDCs often involves complex patent litigation, manufacturing efficiencies, and strategic partnerships.
The market is mature, with competition focused on cost-efficiency and market penetration rather than novel therapeutic differentiation for abacavir sulfate as a standalone entity.
What are the Pricing Trends and Reimbursement Policies Affecting Abacavir Sulfate?
The pricing and reimbursement landscape for abacavir sulfate is predominantly influenced by its status as a generic drug and its role in combination therapies for HIV/AIDS.
Pricing Trends:
- Generic Price Erosion: The introduction of generic abacavir sulfate has led to significant price reductions compared to the original branded product. This is a standard trend for off-patent drugs. Prices vary considerably based on manufacturer, volume of purchase, and geographic market.
- Fixed-Dose Combination (FDC) Pricing: Branded FDCs containing abacavir sulfate, such as Triumeq, command higher prices due to the inclusion of newer agents like dolutegravir and the value of simplified dosing. However, even these are subject to price negotiations and the eventual advent of generic FDCs.
- Wholesale Acquisition Cost (WAC): WAC is the list price. Actual transaction prices are often lower due to rebates, discounts, and volume-based agreements.
- Geographic Variation: Pricing varies significantly between high-income countries (where insured populations and complex reimbursement systems exist) and low- and middle-income countries (where pricing is often driven by global health initiatives and bulk purchasing agreements, such as those facilitated by the Global Fund or PEPFAR).
Reimbursement Policies:
- Formulary Placement: In many healthcare systems, abacavir sulfate and its generic versions are placed on formularies, making them accessible to patients. Reimbursement levels and co-pays depend on the specific formulary rules of insurance providers or national health services.
- Tiered Pricing: For branded FDCs, tiered pricing strategies are common, offering discounts to governments or large purchasers to increase access in resource-limited settings.
- Cost-Effectiveness Analysis: Reimbursement decisions, particularly for newer FDCs, often involve cost-effectiveness analyses. Abacavir-containing regimens are generally considered cost-effective, especially generic versions, when weighed against the long-term costs of untreated HIV.
- Government Programs: Public health programs, such as the U.S. President's Emergency Plan for AIDS Relief (PEPFAR) and initiatives by the Global Fund to Fight AIDS, Tuberculosis and Malaria, are major purchasers of antiretroviral drugs, including abacavir sulfate and its combinations, especially in developing countries. These programs often negotiate significant discounts.
- Managed Care and PBMs: In the U.S. market, Pharmacy Benefit Managers (PBMs) and managed care organizations play a crucial role in negotiating prices and determining patient out-of-pocket costs through their formularies and rebate agreements. They often favor generics for cost savings.
- Mandatory Generic Substitution: In many countries, pharmacists are mandated to substitute generic abacavir sulfate for prescribed branded abacavir sulfate, unless specifically overridden by the prescriber.
The reimbursement environment generally supports access to abacavir sulfate, particularly generic versions, due to its established efficacy and cost-effectiveness in HIV management.
What are the Clinical Efficacy and Safety Profiles of Abacavir Sulfate?
Abacavir sulfate has a well-established clinical efficacy and safety profile based on extensive clinical trials and post-marketing surveillance.
Clinical Efficacy:
- Mechanism of Action: Abacavir is a carbocyclic nucleoside analog that acts as a reverse transcriptase inhibitor. It is intracellularly phosphorylated to carbovir triphosphate, which competes with the natural substrate deoxyguanosine triphosphate and is incorporated into viral DNA. This incorporation leads to chain termination and inhibition of viral DNA synthesis.
- Viral Load Reduction: In combination therapy, abacavir contributes significantly to the reduction of plasma HIV-1 RNA levels (viral load) to undetectable levels.
- CD4+ Cell Count Increase: Treatment with abacavir-containing regimens leads to an increase in CD4+ T-cell counts, which is a marker of immune reconstitution and improved prognosis.
- Efficacy in Treatment-Naive and Treatment-Experienced Patients: Abacavir has demonstrated efficacy in both treatment-naive individuals starting antiretroviral therapy and in treatment-experienced patients switching regimens due to resistance or intolerance.
- Combination Therapy is Key: It is crucial to emphasize that abacavir sulfate is only effective when used in combination with at least two other antiretroviral agents. Monotherapy with abacavir does not prevent the development of resistance.
Safety Profile and Adverse Events:
The primary safety concern associated with abacavir is the risk of a hypersensitivity reaction (HSR).
- Hypersensitivity Reaction (HSR): This is a potentially life-threatening immune-mediated reaction that can occur in approximately 5-8% of patients treated with abacavir.
- Symptoms: HSR symptoms typically begin within the first six weeks of treatment and can include fever, rash (non-vesicular, non-bullous), fatigue, nausea, vomiting, diarrhea, abdominal pain, and respiratory symptoms such as cough or shortness of breath.
- HLA-B*5701 Testing: The development of a screening test for the HLA-B*5701 allele has significantly reduced the incidence and severity of abacavir HSR. Patients who are positive for this allele have a very high risk of developing HSR and should not be treated with abacavir. Approximately 4-5% of individuals of European descent and a much lower percentage of individuals of African descent carry this allele.
- Management: Patients experiencing symptoms suggestive of HSR should discontinue abacavir immediately and seek medical attention. A permanent discontinuation of abacavir is recommended for all patients who experience an HSR.
- Other Adverse Events: Common adverse events, often mild and transient, include:
- Nausea
- Headache
- Fatigue
- Insomnia
- Dizziness
- Anorexia
- Cardiovascular Risk: Some studies and observational data have suggested a potential association between abacavir use and an increased risk of myocardial infarction (heart attack), particularly in patients with pre-existing cardiovascular risk factors. However, this association remains a subject of ongoing research and debate, with some meta-analyses not confirming a significant increased risk when confounding factors are controlled. Regulatory bodies continue to monitor this potential risk.
- Lactic Acidosis and Hepatic Steatosis: Like other nucleoside reverse transcriptase inhibitors (NRTIs), abacavir carries a risk of lactic acidosis and severe hepatomegaly with steatosis, which can be fatal. This risk is higher in women, obese patients, and patients with long-term NRTI use.
- Lipodystrophy: While less common with abacavir compared to some older NRTIs, lipodystrophy (abnormal redistribution of body fat) can occur.
The current clinical practice emphasizes the critical importance of HLA-B*5701 screening before initiating abacavir therapy to mitigate the risk of HSR. Comprehensive patient monitoring for other potential adverse events is also standard practice.
What is the Future Outlook and Potential for Innovation for Abacavir Sulfate?
The future outlook for abacavir sulfate is largely defined by its established role in current HIV treatment paradigms, the dominance of generic competition, and the ongoing evolution of HIV therapeutics.
Established Role and Market Dynamics:
- Continued Use in FDCs: Abacavir sulfate will likely continue to be a component of widely used fixed-dose combinations (FDCs), particularly those with dolutegravir and lamivudine (e.g., Triumeq and its generic equivalents), for the foreseeable future. These FDCs offer well-established efficacy, good tolerability (with HSR screening), and high rates of viral suppression.
- Generic Market Dominance: The market for abacavir sulfate as a standalone API and in generic single-agent formulations is saturated with multiple manufacturers. Competition will remain focused on cost, supply chain reliability, and market access.
- Cost-Effectiveness: Its cost-effectiveness, especially in generic forms, ensures its continued use in resource-limited settings and in public health programs.
Potential for Innovation:
Direct innovation specifically for abacavir sulfate as a single entity is limited due to its mature status and patent expiry. However, potential areas include:
- Novel Combinations: While major FDCs are already established, research might explore new synergistic combinations with emerging antiretroviral agents if significant clinical advantages can be demonstrated. This is less likely given the rapid pace of discovery in HIV.
- Improved Formulations: Innovations in drug delivery, such as extended-release formulations or alternative routes of administration, are unlikely for such an established, orally administered NRTI, especially given the focus on longer-acting injectables for HIV treatment.
- Pediatric Formulations: Refinement of pediatric dosing and formulations might occur, though current offerings are generally adequate.
- Addressing Specific Patient Subpopulations: Research could focus on understanding and managing rare adverse events or optimizing its use in specific patient groups, though this is more an area of pharmacovigilance and clinical guideline refinement than novel product development.
Competitive Pressures and Market Shifts:
- Advancements in Long-Acting Injectables: The development and increasing adoption of long-acting injectable antiretrovirals (e.g., cabotegravir/rilpivirine) represent a significant potential disruptor to oral therapy regimens, including those containing abacavir. These treatments offer improved adherence and convenience, potentially reducing reliance on daily oral pills.
- Development of Novel Drug Classes: The ongoing discovery of new classes of antiretrovirals with different mechanisms of action and potentially improved resistance profiles may gradually shift treatment preferences away from older drug classes.
- Focus on Cure and Eradication: The ultimate goal of HIV research is a cure or functional cure. While abacavir plays a role in managing the virus, it is not a cure. Future therapeutic strategies will likely move beyond viral suppression to eradication or long-term remission strategies.
In summary, abacavir sulfate's future is one of continued, albeit likely stable or declining, use as a foundational component of combination therapy. Its market trajectory is characterized by a mature, genericized landscape facing increasing competition from newer therapeutic modalities, particularly long-acting injectables and potentially future cure-focused strategies.
Key Takeaways
- Abacavir sulfate is a crucial component of HIV treatment, particularly within fixed-dose combinations.
- The market is mature and dominated by generic competition following patent expirations.
- The primary safety concern is the hypersensitivity reaction, significantly mitigated by HLA-B*5701 genetic screening.
- Pricing is driven by generic availability and reimbursement policies, with significant volume in public health programs.
- The future outlook anticipates continued use in established regimens but faces potential disruption from long-acting injectables and novel HIV therapeutics.
Frequently Asked Questions
What is the significance of the HLA-B*5701 genetic test in relation to abacavir sulfate?
The HLA-B*5701 genetic test is critical for identifying individuals at high risk of developing a serious hypersensitivity reaction (HSR) to abacavir sulfate. Patients who test positive for this allele should not be prescribed abacavir due to the high probability of experiencing HSR, which can be life-threatening.
How does abacavir sulfate compare in efficacy to newer antiretroviral drugs?
Abacavir sulfate, when used in combination therapy, demonstrates robust efficacy in reducing viral load and increasing CD4+ cell counts. While newer agents, particularly integrase inhibitors like dolutegravir, often show faster viral suppression and potentially higher barrier to resistance, abacavir-containing regimens remain highly effective and are often preferred due to cost-effectiveness and established safety profiles (post-HSR screening).
Can abacavir sulfate be used to treat Hepatitis B virus (HBV) infection?
Abacavir sulfate is specifically indicated for the treatment of HIV-1 infection. It is not indicated or approved for the treatment of Hepatitis B virus (HBV) infection. While some antiretrovirals used for HIV can also treat HBV, abacavir does not possess this dual activity.
What are the primary challenges associated with the long-term use of abacavir sulfate?
The primary challenge remains the risk of hypersensitivity reaction, even with screening, although rare re-challenge reactions can occur. Other potential long-term concerns include the debated association with cardiovascular events and the general class risks of lactic acidosis and hepatic steatosis associated with nucleoside reverse transcriptase inhibitors.
How does the cost of generic abacavir sulfate compare to its branded originator product?
Generic abacavir sulfate is significantly less expensive than its original branded originator product. This price differential is a direct result of patent expiration and the entry of multiple generic manufacturers into the market, driving down costs through competition.
Cited Sources
- Grand View Research. (2023). HIV Market Size, Share & Trends Analysis Report By Drug Type (Antivirals, Vaccines), By Treatment (Combination Therapy, Monotherapy), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies), By Region, And Segment Forecasts, 2023 - 2030. Retrieved from https://www.grandviewresearch.com/industry-analysis/hiv-market
More… ↓
